ANVISA Updates Rehab Devices Registration: Remote Robots Require Local Clinical Data

On May 6, 2026, Brazil’s National Health Surveillance Agency (ANVISA) issued RDC No. 28/2026, mandating new clinical evidence requirements for remote-controlled rehabilitation devices—including exoskeletons, neurofeedback training systems, and VR-based rehabilitation platforms. This update directly affects medical device manufacturers, importers, and distributors targeting the Brazilian market, signaling a tightening of evidentiary standards for digital and robotic rehab technologies.

Event Overview

On May 6, 2026, ANVISA published Regulatory Directive RDC No. 28/2026. The regulation requires all remote-controlled rehabilitation devices—specifically including exoskeletons, neurofeedback training systems, and virtual reality (VR) rehabilitation platforms—to submit, as part of their registration dossier, a clinical effectiveness report conducted in Brazilian healthcare institutions. The report must cover at least 100 patients and include data on functional improvement rate, treatment adherence, and adverse events. This requirement supplements existing safety testing obligations. A transition period of 90 days is provided from the effective date.

Industries Affected

Medical Device Manufacturers (Remote Rehab Segment)

Manufacturers of remote-controlled rehab devices are directly impacted because the new rule introduces a mandatory local clinical evidence component—not just conformity assessments or foreign trial data. This shifts the regulatory burden from technical documentation alone to locally generated real-world performance validation.

Importers and Distributors of Rehab Technologies

Importers and distributors operating in Brazil must now verify whether incoming products meet the new clinical reporting requirement before submission. Products lacking compliant local clinical reports will not be eligible for registration, potentially halting market entry or renewal processes after the 90-day transition ends.

Contract Research Organizations (CROs) & Clinical Trial Providers in Brazil

CROs with infrastructure in Brazilian hospitals may see increased demand for localized clinical studies supporting device registration. However, the requirement specifies that trials must be conducted in Brazilian healthcare institutions—limiting eligibility to entities with active clinical partnerships and IRB-approved protocols within the country.

Key Considerations and Recommended Actions for Stakeholders

Monitor official ANVISA guidance and implementation clarifications

ANVISA has not yet published detailed templates, acceptable study designs, or definitions of “functional improvement” for this requirement. Stakeholders should track upcoming Q&A documents or public consultations related to RDC No. 28/2026.

Prioritize assessment of high-value remote rehab product lines for Brazil market access

Companies with multiple remote rehab offerings should triage based on commercial priority and feasibility of conducting ≥100-patient studies in Brazil within the 90-day window. Products already undergoing local pilot deployments may have a head start in generating required data.

Distinguish between regulatory signal and operational readiness

The 90-day transition does not imply automatic approval of pending applications. It only sets the deadline for full compliance. Applications submitted before the deadline without the local clinical report will likely be rejected or placed on hold—meaning preparation must begin immediately, not upon submission.

Engage early with Brazilian clinical partners and ethics committees

Initiating protocol development, site selection, and ethics review takes time. Companies without established clinical networks in Brazil should begin outreach now, as institutional review board (IRB) approvals and patient recruitment planning cannot be accelerated post-deadline.

Editorial Perspective / Industry Observation

Observably, this update reflects ANVISA’s growing emphasis on real-world clinical outcomes—not just safety—for digitally enabled medical devices. Analysis shows it is less a sudden policy shift and more an incremental alignment with global trends toward health technology assessment (HTA)-informed regulation. From an industry perspective, RDC No. 28/2026 functions primarily as a procedural gatekeeper rather than a substantive innovation barrier—but its enforcement rigor remains to be observed. Current monitoring should focus on whether ANVISA permits phased submissions (e.g., interim reports) or accepts multicenter studies coordinated across Brazilian institutions.

Conclusion
This regulation marks a formalization of clinical evidence expectations for remote rehabilitation technologies in Brazil. It does not prohibit market access, but redefines the evidentiary threshold for registration. For stakeholders, it is best understood not as a temporary hurdle, but as an indication of ANVISA’s longer-term direction: requiring locally contextualized proof of benefit for digitally mediated therapeutic devices.

Information Sources
Main source: ANVISA Regulatory Directive RDC No. 28/2026, published May 6, 2026.
Note: Details regarding acceptable clinical endpoints, IRB requirements, and transitional application handling remain subject to ongoing clarification by ANVISA and are under observation.